Petrelintide

At a glance

---

What is petrelintide?

Petrelintide is a synthetic, long-acting amylin analog -- a peptide designed to mimic amylin, a hormone your pancreas releases alongside insulin after you eat.^[7] It is given as a once-weekly subcutaneous injection and is being developed for chronic weight management. Its research code is ZP8396.

The compound originated at Zealand Pharma in Denmark. In March 2025, Roche entered an exclusive collaboration to co-develop and co-commercialize petrelintide; Genentech is the Roche Group's US member, which is why you will sometimes see the program described as "Roche/Genentech."^[4] This matters because it puts a large pharmaceutical company's resources behind a Phase 3 program -- but it does not change the regulatory reality: petrelintide is not approved anywhere.

What makes petrelintide notable is the pathway it uses. Most of the headline weight-loss drugs -- semaglutide, tirzepatide, retatrutide -- are built around GLP-1 (and sometimes GIP and glucagon) receptors. Petrelintide instead targets amylin receptors, a complementary mechanism. Its closest direct comparator is cagrilintide, the other leading long-acting amylin analog.

---

How it works

In plain terms, petrelintide mimics amylin, a "fullness" hormone. After a meal, your body releases amylin along with insulin; amylin tells your brain you have eaten enough, slows how quickly food leaves your stomach, and helps restore your sensitivity to leptin (another satiety hormone that often stops working well in obesity).^[7]

This is a different lever than GLP-1 drugs pull. GLP-1 agonists reduce appetite primarily through their own receptor pathway; amylin works largely through the area postrema, a region of the brainstem that senses satiety signals. Because the two pathways are separate but related, they appear to add together -- which is the entire rationale for combination products in this space.^[9]

Detailed mechanism (for advanced readers)

Petrelintide is a long-acting amylin receptor agonist. Native human amylin (also called IAPP) is co-secreted with insulin from pancreatic beta cells and acts on amylin receptors -- heteromers of the calcitonin receptor paired with receptor-activity-modifying proteins (RAMPs).^[7]

Core effects of amylin receptor agonism:

• Satiety signaling: Amylin binds receptors concentrated in the area postrema of the brainstem, which relays to the lateral parabrachial nucleus to suppress appetite.
• Slowed gastric emptying: Food leaves the stomach more slowly, prolonging fullness after meals.
• Restored leptin sensitivity: Amylin appears to re-sensitize the brain to leptin, a hormone whose signaling is often blunted in obesity. This is thought to be central to durable appetite control.

Why a long-acting analog: Native amylin has a very short half-life and a tendency to aggregate, making it impractical as a once-weekly drug. Long-acting amylin analogs are engineered for stability and extended exposure suitable for weekly dosing -- the same design challenge solved for cagrilintide.^[8] Petrelintide's specific peptide engineering and sequence have not been published.

Complementary to GLP-1 (the combination thesis): A Phase 1b study of cagrilintide plus semaglutide showed that adding an amylin analog to a GLP-1 agonist produced greater weight loss than either alone, with the two mechanisms acting additively on appetite.^[9] Roche and Zealand are pursuing this strategy directly, developing petrelintide in combination with Roche's incretin agent enicepatide (CT-388).^[4]

The strategic bet: Because amylin agonism tends to produce less nausea and vomiting than GLP-1 agonism, petrelintide's developers are positioning it as a better-tolerated foundation -- a drug people can actually stay on -- rather than a maximum-efficacy agent.

---

What the research says

Petrelintide's Phase 2 story is unusual: the weight-loss number (~10.7%) is good but not class-leading, while the tolerability number is the actual headline. Whether "double-digit weight loss with placebo-like side effects" wins in a market chasing 20%+ is the open question Phase 3 will answer.

Research timeline

Petrelintide moved from early clinical work to a Phase 3 decision in roughly two years:

Human clinical trials

Petrelintide's human evidence rests almost entirely on a single detailed Phase 2 readout, with a second Phase 2 trial still in progress:

ZUPREME-1 (the readout that matters): A Phase 2b trial in people with overweight or obesity without type 2 diabetes. It enrolled 493 participants across 32 sites and randomized 485 to petrelintide or placebo in a 5:1 ratio. The treatment period was 42 weeks (dose escalation up to 16 weeks), with safety follow-up to week 51 and the primary endpoint assessed at week 28. The population was 53% female, mean age 47, mean BMI 36.7 kg/m², and baseline weight 107.1 kg.^[1]

ZUPREME-2 (still running): A Phase 2b trial in people with overweight or obesity and type 2 diabetes, testing three doses up to 9 mg over 28 weeks. Topline results are expected in the second half of 2026.^[5]

---

What the evidence shows

Petrelintide has attracted attention as a potentially gentler weight-loss drug. Here is what the Phase 2 data actually supports -- and what it does not:

---

Safety & side effects

What the Phase 2 trial shows

Petrelintide's safety profile is based on roughly 485 participants in ZUPREME-1. The standout finding is how little gastrointestinal trouble it caused -- the area where GLP-1 drugs are notorious.^[1]

Gastrointestinal events (ZUPREME-1, petrelintide vs placebo):

• Nausea: 19.6% vs 6.2% placebo -- elevated, but less than half the rate commonly reported with GLP-1 agonists
• Vomiting: 3.0% vs 6.2% placebo -- notably, lower than placebo
• Diarrhea: under 7.5% (both arms)
• Constipation: under 7.5% (both arms)
• More than 75% of GI adverse events were mild

What this means in context

The developers' explicit pitch is adherence. Zealand's leadership framed the goal as "double-digit weight loss with placebo-like tolerability" -- a "sweet spot" for a first-choice medicine that people can actually stay on, rather than the highest possible number on the scale.^[6] Analysts were split: some had expected higher efficacy (over 12%), and Eli Lilly's competing amylin candidate reached roughly 16% in its own Phase 2.^[6] Whether tolerability or raw efficacy wins is a genuine open question.

What we don't know about safety

There are large gaps in the petrelintide safety picture:

• No peer-reviewed data: All safety figures come from a press release and conference presentation, not a published, fully scrutinized trial report.
• No long-term data: The longest exposure is the 42-week ZUPREME-1 treatment period (safety follow-up to week 51). Chronic-use safety is unknown.
• No Phase 3 or post-marketing data: No large registrational dataset and no real-world surveillance exist.
• No T2D safety profile yet: ZUPREME-2 has not reported.
• Lean mass and body composition: The quality of weight lost (fat vs lean mass) has not been detailed publicly.
• No pregnancy or drug-interaction data: Not characterized.
• Amylin-class effects: Long-term effects of sustained amylin receptor agonism in humans are less established than for the GLP-1 class.

---

Legal & regulatory status

As of June 2026:

FDA status

Petrelintide is not FDA-approved for any indication. It is an investigational drug that has completed Phase 2 testing.

• No approved petrelintide product: It is not a component of any FDA-approved drug and has not been found safe and effective for any condition.
• No Breakthrough or other designation publicly announced. Investigational status is a development stage, not a form of approval.
• Not on the July 2026 PCAC agenda: The FDA Pharmacy Compounding Advisory Committee is not reviewing petrelintide.
• Timeline: A Phase 3 chronic-weight-management program is planned to initiate in the second half of 2026.^[3] Phase 3 trials plus FDA review typically take several years, so the earliest plausible approval is well beyond 2026.

How to access petrelintide today

The only legal way to access petrelintide is through enrollment in a clinical trial. Trial listings can be found at ClinicalTrials.gov by searching "petrelintide" or "ZP8396."^[5]

For more on why a Phase 2/3 investigational drug cannot be legally compounded, see Why Investigational Peptides Are Not Compoundable.

WADA / anti-doping status

Petrelintide is not specifically named on the 2026 WADA Prohibited List, and amylin analogs are not currently listed as a class. As an investigational, non-approved substance, it could fall under S0 (Non-Approved Substances) for athletes in some jurisdictions. This is an interpretation, not an official WADA classification.

---

How petrelintide compares

Petrelintide's natural comparators are other amylin analogs (cagrilintide) and the GLP-1/incretin drugs it is positioned against (tirzepatide, semaglutide). No head-to-head trials exist, so these comparisons rely on cross-trial data, which has serious limitations:

The key tradeoffs:

• Weight loss: Tirzepatide leads decisively in cross-trial terms (20–22% vs petrelintide's ~10.7%). Petrelintide is in the same range as cagrilintide as a solo amylin analog. But petrelintide is investigational and these are not head-to-head comparisons.^[1]
• Tolerability: This is petrelintide's argument. Its placebo-like GI profile -- including vomiting below placebo -- contrasts with the nausea and vomiting that drive many people off GLP-1 and incretin drugs.^[1][6]
• Combination potential: Amylin analogs add to GLP-1 agonists. Roche plans to combine petrelintide with its incretin enicepatide (CT-388), aiming to stack petrelintide's tolerability onto incretin-level efficacy.^[4][9]
• Evidence and availability: Tirzepatide is FDA-approved with a large evidence base; petrelintide has one Phase 2 readout and is not available outside trials.

The bottom line: petrelintide is a credible, well-tolerated amylin analog with a single promising Phase 2 trial behind it. Its real test -- both as a standalone weekly drug and as a combination partner -- is the Phase 3 program starting in late 2026. Until then, it is investigational, and the numbers above should be read as early signals, not settled facts.

---

Related content

Peptide

Cagrilintide Profile

The other leading long-acting amylin analog (Novo Nordisk). Same mechanistic class as petrelintide and the closest direct comparator.

Peptide

CagriSema Profile

Cagrilintide combined with semaglutide — the proof that pairing an amylin analog with a GLP-1 agonist boosts weight loss, the strategy Roche plans with petrelintide + enicepatide.

Peptide

Amycretin Profile

A single-molecule GLP-1 + amylin agonist. A useful contrast: amycretin builds amylin activity into one peptide, while petrelintide is a pure amylin analog.

Peptide

Tirzepatide Profile

An FDA-approved incretin benchmark (~20–22% weight loss) against which petrelintide's amylin-driven efficacy and tolerability are measured.

Guide

What Are Peptides?

A foundational primer — helpful context for understanding how amylin analogs like petrelintide differ from GLP-1 drugs.

Guide

Why Investigational Peptides Are Not Compoundable

Explains why a Phase 2/3 investigational drug like petrelintide is trial-only and why research-use vendors are not equivalent to pharmacy access.

Tool

Half-Life and Accumulation Plotter

Visualize how a once-weekly peptide like petrelintide accumulates to steady state over repeated doses.

---

References

1. [1]

   Zealand Pharma A/S. “New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight management experience for people living with overweight and obesity.” 2026. LinkRCT

   Primary press release (June 5, 2026) reporting detailed ZUPREME-1 data presented at ADA 2026. n=485 randomized (493 enrolled, 32 sites); 5:1 vs placebo; 42-week treatment, primary endpoint at week 28. Up to 10.7% weight loss vs 1.7% placebo (efficacy estimand, p<0.001). Vomiting 3.0% (below placebo 6.2%); GI discontinuations 1.5%. Topline — peer-reviewed publication pending.

2. [2]

   F. Hoffmann-La Roche Ltd. “Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity.” 2026. LinkRCT

   Topline ZUPREME-1 readout (March 5, 2026). Met primary endpoint with up to 10.7% mean weight loss vs 1.7% placebo and placebo-like GI tolerability. Predates the detailed ADA 2026 presentation.

3. [3]

   Zealand Pharma A/S. “Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management.” 2026. LinkReview

   April 29, 2026 announcement that the partners will advance petrelintide into a Phase 3 chronic-weight-management program, with initiation planned for the second half of 2026.

4. [4]

   F. Hoffmann-La Roche Ltd. “Roche enters into an exclusive collaboration & licensing agreement with Zealand Pharma to co-develop and co-commercialise petrelintide as a potential foundational therapy for people with overweight or obesity.” 2025. LinkReview

   March 12, 2025 collaboration announcement. US + Europe co-developed and co-commercialized (50/50 profit/loss); Roche exclusive rest-of-world. Genentech is Roche's US member. Combination development planned with enicepatide (CT-388).

5. [5]

   Zealand Pharma A/S. “Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2).” 2025. LinkRCT

   Phase 2b, randomized, double-blind, placebo-controlled trial in overweight/obesity with type 2 diabetes. Three doses up to 9 mg over 28 weeks of treatment. Topline expected H2 2026.

6. [6]

   Hayden D. “ADA: Obesity partners Zealand and Roche aim for weight loss 'sweet spot' with amylin agonist.” BioSpace. 2026. LinkReview

   Independent ADA 2026 coverage. Captures analyst skepticism (William Blair expected >12%; Lilly's eloralintide ~20% in Phase 2) alongside the company 'tolerability sweet spot' framing. Provides honest cross-trial comparison context.

7. [7]

   Boyle CN, Lutz TA, Le Foll C. “Amylin — Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity.” Mol Metab. 2018. 8:203–210 DOI PubMedReview

   Foundational review of amylin physiology: area postrema signaling, satiety, slowed gastric emptying, and restoration of leptin sensitivity — the class mechanism petrelintide belongs to.

8. [8]

   Kruse T, Hansen JL, Dahl K, et al.. “Development of Cagrilintide, a Long-Acting Amylin Analogue.” J Med Chem. 2021. 64(15):11183–11194 DOI PubMedIn vitro

   Medicinal-chemistry context for long-acting amylin analogue design (the class to which petrelintide belongs). Petrelintide's own peptide-engineering paper is not yet published; its sequence and full structure remain undisclosed.

9. [9]

   Enebo LB, Berthelsen KK, Kankam M, et al.. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.” Lancet. 2021. 397(10286):1736–1748 DOI PubMedRCT

   Demonstrates additive/complementary weight loss when an amylin analogue is combined with a GLP-1 agonist — the rationale behind petrelintide + enicepatide (CT-388) combination development.

10. [10]

    U.S. Food and Drug Administration. “FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” 2026. LinkSafety study

    FDA safety communication on unapproved weight-loss peptides sold online (research-use labeling, no human-consumption disclaimers). Used to frame why an investigational amylin analogue like petrelintide cannot be legally compounded or purchased.

---